NeoplasmsPost-essential thrombocythemiaMyelodysplastic syndromesMyelofibrosisThrombosisPatientsClinicalMutationsWeight heparinGeneticsJAK2EssentialDisordersPlateletSecondaryAbstractChronic myeloidErythropoiesisBone2022HematopoieticImmunologyEfficacyMechanism of actMechanismsBiotechnologyGenetic testsPrimaryTreatmentHematocritReceptorCellNormalStudiesProteinChemical
Neoplasms4
- Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. (medscape.com)
- Philadelphia-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). (researchgate.net)
- INTRODUCTION - An overview of the four classic myeloproliferative neoplasms (MPN): polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia will be presented here. (medilib.ir)
- Activating point mutations in the JAK2 kinase were identified in BCR-ABL-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis (MF). (uzh.ch)
Post-essential thrombocythemia1
- This encouraged the development of several small-molecule JAK2 tyrosine kinase inhibitors, of which ruxolitinib (formerly known as INCB018424) was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk MF, including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. (uzh.ch)
Myelodysplastic syndromes1
- It is comprised of cancers in chronic and acute stages, including myelodysplastic syndromes (MDS), chronic myeloid leukemia, polycythemia vera, and acute myeloid leukemia (AML). (innoget.com)
Myelofibrosis5
- The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. (medscape.com)
- Conventional treatments for the BCR-ABL1-negative MPN including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have, so far, been unsatisfactory. (eurekaselect.com)
- Subtypes include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). (researchgate.net)
- MPNs include polycythemia vera, essential thrombocythemia, chronic myeloid leukemia (CML), primary myelofibrosis, chronic neutrophilic leukemia, and other less well defined entities such as chronic eosinophilic leukemia, not otherwise categorized. (medilib.ir)
- The most common (classic) MPNs are chronic myeloid leukemia ( CML ), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). (amboss.com)
Thrombosis1
- JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. (medscape.com)
Patients10
- Some patients with polycythemia vera are asymptomatic, whereas others have various nonspecific symptoms. (medscape.com)
- von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. (cdc.gov)
- The prevalence of JAK2 exon12 mutations in Vietnamese patients with JAK2 V617F-negative polycythemia vera: frequent or rare? (cdc.gov)
- Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. (cdc.gov)
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. (medscape.com)
- Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. (medscape.com)
- Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. (medscape.com)
- The goal of therapy for essential thrombocythemia (ET) and polycythemia vera (PV) patients is to reduce thrombotic events by normalizing blood counts. (ox.ac.uk)
- 12. Ruggeri M., Tosetto A., Frezzato M., Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis // Ann. (medline.ru)
- Our second model is a Jak2 V617F knock-in model that closely resembles characteristics of polycythemia vera (PV) patients. (wustl.edu)
Clinical6
- Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera]. (cdc.gov)
- Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. (medscape.com)
- This review addresses the cellular and molecular biology, and the clinical management of MPN. (eurekaselect.com)
- Secondary polycythemia (SP) is a poorly understood clinical entity. (nature.com)
- The diagnostic approach proposed by the World Health Organization (WHO) uses clinical features, bone marrow (BM) morphology, karyotype and molecular genetic tests to classify MPN su. (researchgate.net)
- See "Clinical manifestations and diagnosis of polycythemia vera" . (medilib.ir)
Mutations2
- Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. (medscape.com)
- CSF3R ), and high-molecular risk mutations. (amboss.com)
Weight heparin1
- The anticoagulation medications include injectables such as heparin or low molecular weight heparin, or tablets to be taken orally, such as apixaban, dabigatran, rivaroxaban and warfarin. (singhealth.com.sg)
Genetics2
- Molecular genetics & genomic medicine 2022 Aug e2044. (cdc.gov)
- Although older chemotherapeutic drugs are often toxic to normal cells, advances in genetics and cellular and molecular biology have led to development of more selective drugs. (msdmanuals.com)
JAK25
- The aim of this study is to analyze the phenotypic divergence between polycytemia vera (PV) and essential thrombocytemia (ET) to find novel therapeutics targets by a proteomic and functional approach to identify alternative routes to JAK2 activation. (biomedcentral.com)
- Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase. (elsevierpure.com)
- In parallel, other JAK inhibitors with potential for pathologic and molecular remissions, less myelosuppression, and with greater selectivity for JAK1 or JAK2, and the ability to overcome JAK inhibitor persistence are in various stages of development. (pvreporter.com)
- In addition, no structural data of ruxolitinib or SAR302503 bound to the JAK2 kinase domain that would reveal their binding modes and molecular mechanism-of-action are available. (uzh.ch)
- Here, we present a near-kinome-wide survey of the specificity of ruxolitinib and SAR302503 and determine their binding modes to the JAK2 kinase domain by extensive sampling using molecular dynamics (MD) simulations. (uzh.ch)
Essential3
- Molecular chaperones are essential for stabilizing the fragile structures of many receptors, protein kinases, and transcription factors that participate in the pathways of normal cellular growth. (biomedcentral.com)
- Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. (cdc.gov)
- A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia. (ox.ac.uk)
Disorders2
- This new edition contains everything that has made Williams Hematology the go-to resource for decades and has been updated with new chapters and critical new research into the molecular mechanisms responsible for hematological disorders and the impact on diagnosis and treatment. (digibookee.com)
- 3. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense // Blood. (medline.ru)
Platelet1
- The haematocrit and platelet target in polycythemia vera. (medscape.com)
Secondary4
- Once polycythemia vera is suspected, the first step in evaluating a patient is determining whether the patient has primary, secondary, or apparent polycythemia. (medscape.com)
- In contrast, the ferritin level is usually normal in secondary polycythemia. (medscape.com)
- Polycythemia vera (PV) is a clonal disorder resulting from neoplastic transformation of hematopoietic stem cells, while secondary polycythemia (SP) is a disease characterized by increased absolute red blood cell mass caused by stimulation of red blood cell production. (nature.com)
- Polycythemia vera (PV) and secondary polycythemia (SP) are hematological diseases characterized by erythropoiesis exacerbation. (nature.com)
Abstract1
- abstract = "Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. (wustl.edu)
Chronic myeloid1
- See also " Polycythemia vera " and " Chronic myeloid leukemia " for further detail on these conditions. (amboss.com)
Erythropoiesis1
- Crielaard BJ, Rivella S. ß-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis. (medscape.com)
Bone1
- Bone marrow and aspirate in polycythemia vera tend to be hypercellular. (medscape.com)
Hematopoietic1
- Polycythemia vera (PV) is a disorder of the multipotent hematopoietic stem cell that manifests as excess production of normal erythrocytes and variable overproduction of leukocytes and platelets. (medscape.com)
Immunology1
Efficacy1
- Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C. Efficacy and safety of low-dose aspirin in polycythemia vera. (medscape.com)
Mechanism of act1
- Although GH is known to upregulate Star gene expression in Leydig cells, its molecular mechanism of action remains unknown. (bvsalud.org)
Mechanisms2
- 5. Kaushansky K. The molecular mechanisms that control thrombopoiesis // J. Clin. (medline.ru)
- In the present review, we focus our attention on the molecular mechanisms leading to oxidative stress-mediates. (researchgate.net)
Biotechnology1
- The use of protein-based medicines has increased because of advancements in molecular biology engineering and biotechnology . (precedenceresearch.com)
Genetic tests1
- Proteomic screening methods to find new physiopathogenic candidate proteins have not been widely employed in cancer, although a large number of molecular genetic tests have been performed with variable results. (biomedcentral.com)
Primary1
- Typically in primary polycythemia, the ferritin level is low due to constant overproduction of erythrocytes. (medscape.com)
Treatment6
- Treatment of polycythemia vera depends on whether the disease is in the plethoric phase or the spent phase. (medscape.com)
- A fourth trial begun in 2023 for the treatment of polycythemia vera is ongoing. (wikipedia.org)
- Interferon alfa: effects of long-term treatment for polycythemia vera. (medscape.com)
- Recombinant interferon-alpha for treatment of polycythaemia vera. (medscape.com)
- Gefitinib is a kind of highly-specific anti-tumor targeted therapy drugs developed by the United Kingdom AstraZeneca, being the first molecular targeted drug for the treatment of non-small cell lung cancer. (lookchem.com)
- And as you said, Dr. Rochester, the testing, when we get those molecular results back, that's going to help us figure out what's going on in that tumor that might change our treatment options, because there's a driver mutation where there's a new drug approved that's going to be the best efficacious opportunity for that patient. (powerfulpatients.org)
Hematocrit1
- In the plethoric phase, polycythemia vera is treated first by performing phlebotomy until the hematocrit is under reasonable control. (medscape.com)
Receptor1
- The small molecule compound, Erlotinib is a receptor tyrosine kinase inhibitor (EGFR antagonist) and belongs to molecular targeted therapy Drugs. (lookchem.com)
Normal1
- The reduced FAD state is converted back to its normal resting oxidized state by molecular oxygen with the production of hydrogen peroxide while the larger cinnamaldehyde fragment, rather than diffusing away from the active site, is able to react in situ with the oxidized FAD to form a stable covalent adduct, effectively locking the LSD1/CoREST complex into a permanently inactivated state. (wikipedia.org)
Studies1
- Jewish download moving viewers: american, like the part of East Asia, claims in the answer studies except on the Sea of Japan grip where many German people need a biology in shared rearmament and philosophical daughter. (yagowap.com)
Protein1
- His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. (stanford.edu)
Chemical1
- Nathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). (stanford.edu)